Drugs / T-Vec
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04427306 | May 2020 → Jun 2022 | melanoma | University of California, Davis | Suspended | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-09-17 | Amgen | Results Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019 amgen.com ↗
Data showing the two-year results of a Phase 2 trial in patients with neoadjuvant melanoma being treated with IMLYGIC ® (talimogene laherparepvec) plus surgery versus immediate surgery will be presented as a late-breaking abstract in an oral presentation. |
| 2015-09-14 | Amgen | Results Amgen Highlights Key Clinical Data To Be Presented At European Cancer Congress 2015 amgen.com ↗
Durable complete responses (CR) in patients (pts) with stage IIIB-IV melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-09-17 | Amgen | Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019 amgen.com ↗ |
| 2015-09-14 | Amgen | Amgen Highlights Key Clinical Data To Be Presented At European Cancer Congress 2015 amgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-VEC | “Talimogene laherparepvec (T-VEC) is the only phase III approved intra-lesional therapy in melanoma” NCT04427306 ↗ |
| Route | Other | “intra-lesional therapy with T-VEC” NCT04427306 ↗ |